==== Front Intensive Care Med Exp Intensive Care Med Exp Intensive Care Medicine Experimental 2197-425X Springer International Publishing Cham 319 10.1186/s40635-020-00319-x Review Fluids in ARDS: more pros than cons Mendes Renata de S. renata_mendes1981@hotmail.com 1 Pelosi Paolo ppelosi@hotmail.com 23 Schultz Marcus J. marcus.j.schultz@gmail.com 456 Rocco Patricia R. M. prmrocco@gmail.com 1 http://orcid.org/0000-0001-5838-4949Silva Pedro L. pedro.leme@gmail.compedroleme@biof.ufrj.br 1 1 grid.8536.80000 0001 2294 473XLaboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Centro de Ciências da Saúde, Avenida Carlos Chagas Filho, s/n, Bloco G-014, Ilha do Fundão, Rio de Janeiro, RJ 21941-902 Brazil 2 grid.5606.50000 0001 2151 3065Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy 3 San Martino Policlinico Hospital, IRCCS for Oncology and Neurosciences, Genoa, Italy 4 grid.7177.60000000084992262Department of Intensive Care, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands 5 grid.10223.320000 0004 1937 0490Mahidol Oxford Tropical Medicine Research Unit (MORU), Mahidol University, Bangkok, Thailand 6 grid.4991.50000 0004 1936 8948Nuffield Department of Medicine, University of Oxford, Oxford, UK 18 12 2020 18 12 2020 12 2020 8 Suppl 1 3218 6 2020 23 6 2020 © The Author(s) 2020Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.In acute respiratory distress syndrome (ARDS), increased pulmonary vascular permeability makes the lung vulnerable to edema. The use of conservative as compared to liberal fluid strategies may increase the number of ventilator-free days and survival, as well as reduce organ dysfunction. Monitoring the effects of fluid administration is of the utmost importance; dynamic indexes, such as stroke volume and pulse pressure variations, outperform static ones, such as the central venous pressure. The passive leg raise and end-expiratory occlusion tests are recommended for guiding fluid management decisions. The type of intravenous fluids should also be taken into consideration: crystalloids, colloids, and human albumin have all been used for fluid resuscitation. Recent studies have also shown differences in outcome between balanced and non-balanced intravenous solutions. In preclinical studies, infusion of albumin promotes maintenance of the glycocalyx layer, reduces inflammation, and improves alveolar-capillary membrane permeability. Fluids in ARDS must be administered cautiously, considering hemodynamic and perfusion status, oncotic and hydrostatic pressures, ARDS severity, fluid type, volume and infusion rate, and cardiac and renal function. Of note, no guideline to date has recommended a specific fluid composition for use in ARDS; most physicians currently follow recommendations for sepsis. Keywords Acute respiratory distress syndromeBalanced solutionNon-balanced solutionsColloidsHuman albuminHemodynamichttp://dx.doi.org/10.13039/501100003593Conselho Nacional de Desenvolvimento Científico e Tecnológico304283/2018-5Silva Pedro L. http://dx.doi.org/10.13039/501100004586Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de JaneiroE-26/202.651/2018Silva Pedro L. 4th International Symposium on Acute Pulmonary Injury and Translational Research - INSPIRES 2019 INSPIRES IVDresden, Germany 25-26 November 2019 issue-copyright-statement© The Author(s) 2020 ==== Body Background Acute respiratory distress syndrome (ARDS) is a multifactorial syndrome caused by different etiologies, which can be pulmonary or extrapulmonary [1]. A major feature of ARDS is increased pulmonary vascular permeability [2]; consequently, interstitial and alveolar edema are hallmarks of its pathophysiology. In addition, lung inflammation, damage to epithelial and endothelial cells, disruption of the extracellular matrix [3], and coagulation disturbances [4] have been recognized. Mitigating lung edema, accelerating its resorption, and maintaining systemic perfusion and distal organ function through modulation of fluid intake seem to be beneficial in ARDS. Several issues should be considered during fluid infusion in this patient population: (1) the etiology, severity, and phase of ARDS; (2) static and dynamic methods to monitor fluid administration; (3) the type of fluids (crystalloids versus colloids, balanced versus non-balanced solution); and, (4) if albumin is used, its concentration. The present review will discuss recent studies on different fluid types and strategies and their effects on the aforementioned aspects of ARDS. Importance of ARDS pathophysiology when choosing the amount and type of fluids Early ARDS is characterized by increased alveolar-capillary barrier damage, which results in lung edema, as well as reduced peripheral perfusion [4]. Increased lung water content impairs lung mechanics and gas exchange, leading to hypoxemia and increased risk of pulmonary arterial hypertension. Moreover, the presence of lung edema perpetuates lung inflammation and epithelial cell damage, thus reducing surfactant production and hindering edema reabsorption [4, 5]. Choosing the optimal fluid strategy (both regarding quantity and type of fluid) is one of the greatest clinical challenges in ARDS management, since both impaired hemodynamics and electrolyte disturbances must be corrected [6, 7], but either one may exacerbate pulmonary edema. Starling’s classic model states that transvascular fluid exchange depends on a balance between hydrostatic and oncotic pressure gradients (Fig. 1) [8]. However, this theory has been considered inconsistent with our new understanding of the role of the glycocalyx [9]. It is now known that the interstitial space has a high protein concentration [8], which weakens the concept of fluid flow direction being guided solely by the difference in capillary and interstitial oncotic pressures. On the other hand, the subglycocalyx space is also responsible for oncotic pressure gradients (Osg) that may determine the transcapillary flow. The functional barrier created by the endothelial glycocalyx layer—which is composed of a glycoprotein skeleton, proteoglycans, and interactions with circulating cells and plasma constituents, including albumin—forms an endothelial surface up to 1 μm thick [8]. The luminal side of the endothelium, below this “protein sponge,” is permanently removed through small breaks (clefts) in the intercellular junction chains to adjacent tissues [10], thus creating an inwardly directed oncotic force (Oip), quantitatively opposed to hydrostatically (Hcp) driven fluid filtration (Fig. 2). Lymph vessels are responsible for the return of fluid to the circulation, which is regulated through sympathetically mediated responses [8]. Although albumin infusion may improve or maintain vascular barrier competence, experiments with isolated organs show that the surface functions well until the albumin concentration falls below 10 g/L [11]. Therefore, it is very likely that the major insult to the vascular barrier leading to its dysfunction is not hypoalbuminemia, but damage to the endothelial glycocalyx. Several factors are associated with glycocalyx damage, such as hypervolemia [12], rapid crystalloid infusion [13], ischemia-reperfusion [14], inflammation [8], sepsis [15], hyperglycemia [16], trauma [17], and altered plasma pH [18]. The glycocalyx is the first and the primary source of resistance to the stream of fluid and solutes between plasma and lymph. Compaction of endothelial glycocalyx and the consequent increase in levels of glycosaminoglycans (GAGs—heparan, hyaluronic acid, or chondroitin) in plasma are considered markers of glycocalyx injury [19, 20]. In this context, circulating levels of syndecan-1 and GAGs have been found elevated in septic patients [15, 21, 22] and are associated with disease severity and worse outcomes [21]. Fig. 1 Fluid filtration according to the classic Starling model. Fluid filtration is mainly guided by the difference between the hydrostatic gradient [hydrostatic capillary pressure (Hcp) and hydrostatic interstitial pressure (Hip) multiplied by K (permeability index)] and oncotic gradient [oncotic capillary pressure (Ocp) and oncotic interstitial pressure (Oip) multiplied by δ (reflection coefficient)]. The interstitial space (IS) is considered to have a low protein concentration [Ptn]. Residual fluids situated in the IS would return to the plasma compartment guided mainly by Ocp; little fluid would return through the lymph vessels Fig. 2 New fluid filtration model. This model proposes that the glycocalyx, which is composed of a glycoprotein skeleton and proteoglycans, interacts with circulating cells and plasma constituents (including albumin) to form an endothelial surface up to 1 μm thick. The interstitial space is considered to have a high protein concentration (Ptn) and, thus, a high oncotic interstitial pressure (Oip), which decreases fluid return to the plasma compartment. Additionally, due to the retention of human albumin molecules in the glycocalyx layer, this structure may generate its own oncotic pressure (Osg), which further jeopardizes fluid return to the plasma compartment. The residual fluid volume in the IS in this model is much greater than in the classic Starling model, and excess fluid may return through the lymph vessels Fluid volume and monitoring in ARDS patients Conservative fluid replacement strategies have been recommended to prevent lung edema. These strategies are associated with less invasive mechanical ventilation, less organ dysfunction, and a trend toward less renal replacement therapy [6, 23]. A recent systematic review and meta-analysis showed that conservative or deresuscitative fluid strategies resulted in an increased number of ventilator-free days and a decreased length of ICU stay compared with a liberal strategy or standard care in adults and children with ARDS, sepsis, or systemic inflammatory response syndrome. Nevertheless, the effect on mortality remains uncertain [6]. In an attempt to better identify those patients who would benefit from fluid replacement, aldosterone and B-type natriuretic peptide (BNP) have been assessed as possible outcome predictors. The authors found that lower levels of aldosterone seem to identify ARDS patients for whom conservative fluid management may improve mortality, while BNP levels did not predict outcomes [24]. In a recent study, conservative fluid management was found to improve mortality in black patients with ARDS [25], suggesting that fluid strategies may be personalized in the future. Hemodynamic monitoring To date, no ideal method has been developed to continuously monitor the response to fluid replacement in ARDS. Four questions have been described to guide fluid strategy in patients with septic shock: “When to start intravenous fluids?”, “When to stop intravenous fluids?”, “When to start de-resuscitation or active fluid removal?”, and, finally, “When to stop de-resuscitation?” [7]. These questions are also pertinent when dealing with non-sepsis states [7]. Several tests and devices are available to predict fluid responsiveness [26]. Static markers of cardiac preload, such as central venous pressure (CVP), do not reliably predict fluid responsiveness; dynamic indexes should be used instead [27]. Dynamic indexes to predict fluid responsiveness The passive leg raise test The passive leg raise test (PLR) [28] consists of moving a patient from the semi-recumbent position to a position where the legs are lifted at 45° and the trunk is horizontal. The transfer of venous blood from the lower limbs and the splanchnic compartment toward the cardiac cavities mimics the increase in cardiac preload induced by a fluid bolus of roughly 300 ml [28]. This test is able to predict fluid responsiveness [29]; the threshold to define responsiveness is a 10% increase in stroke volume and/or cardiac output (CO) after PLR. Stroke volume variation (SVV) and pulse pressure variation (PPV) SVV and PPV, derived from the arterial pressure signal, represent the influence of the periodic increase in intrathoracic pressure due to invasive mechanical ventilation. For SVV and PPV to be accurate predictors of fluid responsiveness, at least four conditions are necessary: sedation and paralysis, tidal volume (VT) ≥ 8 ml/kg, regular heart rhythm, and respiratory system compliance ≥ 30 ml/cm H2O [30, 31]. Several studies have shown that an SVV greater than 10% or a PPV greater than 13–15% are predictive of fluid responsiveness [32]. The end-expiratory occlusion (EEO) test The EEO test is easy to perform in patients under invasive mechanical ventilation [33]. Ventilation is briefly interrupted (15–30 s), which increases the right cardiac preload to its maximum value. Depending on the duration of occlusion, transmission occurs to the left side. An increase in stroke volume is indicative of preload responsiveness [33]. The EEO test proved reliable in several settings [34, 35], especially when VT ≥ 8 ml/kg, but not with VT = 6 ml/kg [36]. Therefore, caution is warranted in the use of the test, since a protective tidal volume is always recommended in ARDS. EEO may predict fluid responsiveness even in prone position and during the Trendelenburg maneuver [37]. Types of fluids in ARDS It is well established that, due to the potential impact on alveolar-capillary membrane damage and lung edema, the type of fluid infused may influence ARDS outcome [38, 39]. However, there is no consensus to date regarding the best fluid for use in ARDS. Crystalloids versus colloids The ALBIOS trial study evaluated 1818 critically ill patients and randomized them to two types of replacement fluid: 20% albumin plus crystalloid or crystalloid only. In the intervention group, the goal of therapy was to achieve plasma albumin levels > 30 g/L. There was no difference in overall mortality at 28 days. An ongoing trial (NCT03869385) was designed to assess the impact of 20% albumin with crystalloid with a target albumin level of > 30 g/L in patients with septic shock, with 28-day mortality as the primary endpoint. Another ongoing clinical trial (NCT03654001) is comparing 20% albumin plus balanced solutions, 20% albumin plus saline, and balanced solutions alone in septic shock. No clinical trial has evaluated albumin or other types of fluids specifically in ARDS, and none is ongoing. Balanced versus non-balanced Crystalloids can also be categorized as balanced or non-balanced (unbalanced) solutions. Balanced solutions contain a precursor anion of bicarbonate in their composition: lactate in Ringer’s lactate, acetate in Ringer’s acetate and Plasma-Lyte®, and others such as gluconate, malate, citrate, and succinate in less commonly used solutions [40]. Non-balanced solutions (such as 0.9% NaCl) are unbuffered and have higher chloride content. Balanced solutions provide some advantages, not least the choice of anion: they (1) replace bicarbonate, (2) are rapidly metabolized, (3) are nontoxic, and (4) maintain pH at 4–8, minimizing hemolysis and endothelial cell damage in peripheral circulation [40]. However, some issues unique to each of the different anions used in balanced solutions must be taken into account before choosing one. For example, almost 70% of infused lactate will participate in gluconeogenesis, being converted to pyruvate and potentially destabilizing glycemic control [41]. Pyruvate follows the Krebs cycle via acetyl-coA, generating carbon dioxide. If lactate accumulates, glycolysis is delayed at the glyceraldehyde-3-phosphate stage, thus reducing ATP generation [41]. On the other hand, acetate has certain theoretical advantages over lactate, as it is metabolized more rapidly (300 mmol/h) and completely (i.e., without accumulating). Acetate does not lead to hyperglycemia and has less effect on oxygen consumption and carbon dioxide elimination. Furthermore, unlike lactate, acetate is metabolized in various non-hepatic tissues, particularly muscle, so is less subject to accumulation in shock or liver dysfunction. The half-life of unbalanced solutions is longer than that of balanced solutions [42], which should be considered when choosing fluid type in different clinical scenarios. Finally, the higher chloride concentration of unbalanced solutions leads to reduced renal flow and increased renal injury [43, 44]. However, clinical studies comparing balanced versus unbalanced crystalloids in intensive care have shown conflicting results regarding renal outcomes and mortality [44–48]. The SPLIT study randomized 2278 patients to receive Plasma-Lyte® versus 0.9% saline [47]. There was no difference in the proportion of patients with acute, moderate, or severe renal injury. (Nevertheless, it bears stressing that the SPLIT study enrolled patients at low risk of acute kidney injury and that the average volume of fluid infused was less than 2000 mL). The SMART study randomized 15,802 patients to receive 0.9% saline versus balanced crystalloid (Ringer lactate or Plasma-Lyte®) in five intensive care units [49]. The authors showed an association between reduced risk of major renal effects (need for renal replacement therapy, death and/or creatinine at endpoint > 200% at admission) and the use of balanced solutions. In an emergency department setting, the SALT-ED study included non-critically ill patients and compared 0.9% saline versus ringer lactate or Plasma-Lyte® [50]. Although mortality at 28 days did not differ between groups, fewer renal adverse events were observed in the group receiving balanced solutions. Colloids Colloids are water-based solutions containing permeable ions and non-permeable molecules, which can be plasma-derived (albumin) or synthetic (gelatins, starches, and dextran) and are unable to cross intact semipermeable biological membranes. The intravascular duration of colloid-derived volume expansion depends on the rate of metabolism and clearance of its constituent molecules [51]. Colloid turnover is described according to the elimination half-life of the oncotic macromolecules contained in the fluid. The half-life of crystalloids is usually expressed in minutes, while elimination of colloids can take hours [42]. Importantly for clinical practice, these elimination half-lives do not reflect the duration of plasma expansion, which is much shorter. This means that macromolecules persist for many hours outside the bloodstream, impregnating renal tissue and thus promoting osmotic nephrotic injury [52], urinary hyperviscosity (which causes tubular obstruction), and inflammation [53]. Synthetic colloids have a well-established association with severe adverse events [54]; human albumin remains under clinical evaluation in this respect. Albumin in ARDS Human albumin is commercially available in several concentrations: iso-oncotic (5%) and hyper-oncotic (20% and 25%) [55]. However, few studies have compared these concentrations in terms of impact on clinical outcomes. Albumin has many other properties in addition to its effects on intravascular volume, including antioxidant activities and molecular transport [55]. Clinical research has shown improvement in physiological parameters after human albumin administration with or without furosemide in patients with ARDS [56]. The antioxidant effect of albumin is related to its capacity to bind iron and copper, thus reducing the availability of these components for pro-oxidant reactions [57]. Changes in albumin concentration and structure during critical illness can lead to significant changes in homeostasis, metabolism, and drug distribution and efficacy [57]. Antimicrobial binding capacity has been shown to be decreased in patients with hypoalbuminemia [58]. These changes may result in inadequate treatment, particularly for time-dependent antibiotics, which may require dose adjustments [58]. Albumin can also protect the microvasculature and attenuate increased vascular permeability by reducing capillary bed leakage [59, 60]. Finally, there is an inverse association of albumin concentration with levels of several pro-inflammatory cytokines [61]. Lung tissue endothelial VE-cadherin expression is reduced in ARDS [3]. In vitro studies have reported rupture of endothelial adherens junctions, corroborating this clinical finding [62]. Reduction of VE-cadherin expression has been associated with increased vascular permeability in ARDS [3] (Fig. 3a). In experimental ARDS, both iso- (4%) and hyper-oncotic (20%) human albumin preserved the integrity of the endothelial barrier compared to Ringer lactate [63], in a mechanism apparently mediated by reduced lung inflammation [64]. Fig. 3 a Before human albumin infusion. In ARDS, glycocalyx content is reduced and its function may be impaired depending on the stage of disease. Due to increased levels of pro-inflammatory mediators in the alveolar compartment, neutrophils are chemoattracted to the alveolar space, trespassing and causing damage to both endothelial cell junctions (e.g., VE-cadherin) and epithelial cell junctions (e.g., E-cadherin). Therefore, alveolar-capillary membrane damage increases, thus contributing to interstitial and alveolar edema. Activation of neutrophils in the alveolar space may promote the release of elastase and the production of neutrophil extracellular traps (NETs). Clot formation is increased, leading to aggregation of platelets into fibrin nets, which impair ventilation-perfusion ratio and decrease oxygenation. b After human albumin infusion. Human albumin is able to reduce levels of pro-inflammatory mediators in the alveolar compartment. Theoretically, this would reduce neutrophil attraction to the alveoli, thus reducing endothelial and epithelial cell damage and leading to decreased alveolar-capillary membrane permeability and lung edema. Human albumin is also able to maintain the glycocalyx connected to the luminal surface of endothelial cells. Finally, due to its heparin-like molecular structure, human albumin is able to reduce clot formation, which might improve ventilation-perfusion ratio and oxygenation Activation of endothelial cells (by microorganisms, toxins, or ischemia-reperfusion injury) leads to the production of mediators (such as angiopoietin-2) and neutrophil infiltration, thus increasing lung vascular permeability. Neutrophil-mediated epithelial injury has been associated with multiple mechanisms: tumor necrosis factor (TNF)-α, neutrophil extracellular traps (NETs), and TNF-related apoptosis-inducing ligand (TRAIL) [65, 66]. In preclinical ARDS studies, albumin attenuated lung damage by reducing oxidative stress and pulmonary inflammation [38, 39, 63]. However, in vitro [67] and in vivo [68] studies reported that hyper-oncotic albumin (20–25%) was associated with renal dysfunction proportional to its concentration. Accordingly, in endotoxin-induced ARDS, iso-oncotic albumin (4%) reduced both lung and kidney damage [63]. A meta-analysis found that albumin improved oxygenation but did not affect mortality in ARDS [69]. Activation of the coagulation cascade is also involved in the pathophysiology of ARDS [70]. Albumin has the ability to inhibit platelet aggregation in a heparin-like manner, albeit with lower potency [71], due to structural similarities between the two. Therefore, in theory, albumin replacement may attenuate the coagulation cascade in ARDS when administered at the right time and dose. In critically ill patients, albumin administration resulted in prolonged activated partial thromboplastin time (APTT) [72]. In vitro studies using thromboelastometry measurements reported impaired clot formation in the hyper-oncotic compared to iso-oncotic albumin group [73]. The hypoalbuminemia often presents in cancer and critical illness may contribute to venous thromboembolism [73]. Albumin reduces lung edema and restores/maintains glycocalyx integrity in experimental ARDS [63]. Perhaps accordingly, iso-oncotic and hyper-oncotic albumin were associated with less lung edema compared with Ringer lactate in the same study [63]. Furthermore, albumin reduced glycocalyx damage in experimental models of ARDS induced by ischemia-reperfusion [8, 74, 75] and hemorrhagic shock [76] (Fig. 3b). Conclusion ARDS is characterized by lung edema and damage to alveolar epithelium, endothelium, and extracellular matrix. Fluid administration is thus very challenging in these patients, since it can increase cardiac output and peripheral perfusion—thus improving tissue oxygenation and organ function—but may also result in serious adverse events. Fluid overload may be particularly dangerous in ARDS due to the possibility of worsening pulmonary edema. Different methods have been used to assess the appropriateness of fluid infusion. However, clinical parameters frequently employed at bedside, such as mean arterial pressure, urine output, oxygen consumption, lactate, and central/mixed venous oxygen saturation, are actually of little use. Static monitoring parameters (e.g., central venous pressure) are unreliable markers of fluid responsiveness; thus, dynamic parameters (PLR, SVV, PPV, and EEO) have been recommended instead. In short, fluids in ARDS must be administered cautiously, considering hemodynamic and perfusion status, oncotic and hydrostatic pressures, ARDS severity, fluid type, volume and infusion rate, and cardiac and renal function. To date, there is no published evidence to recommend any specific fluid composition over another in ARDS, and most physicians follow recommendations designed for sepsis instead. Further research is needed to help elucidate this issue with a view to improving clinical management of ARDS. Abbreviations ARDSAcute respiratory distress syndrome APTTActivated partial thromboplastin time BNPB-type natriuretic peptide COCardiac output CVPCentral venous pressure EEOEnd-expiratory occlusion test GAGsGlycosaminoglycans HcpHydrostatic capillary pressure HipHydrostatic interstitial pressure ISInterstitial space NETNeutrophil extracellular trap OsgOncotic pressure OipOncotic interstitial pressure OcpOncotic capillary pressure PLRPassive leg raise test PPVPulse pressure variation SVVStroke volume variation TNF-αTumor necrosis factor alpha TRAILTNF-related apoptosis-inducing ligand VTTidal volume Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Dr. Rocco and Dr. Silva share senior authorship. Acknowledgements We thank Mrs. Moira Elizabeth Schottler and Mr. Filippe Vasconcellos for their assistance in editing the manuscript. About this supplement This article has been published as part of Intensive Care Medicine Experimental Volume 8 Supplement 1, 2020: Proceedings from the Fourth International Symposium on Acute Pulmonary Injury and Translation Research (INSPIRES IV). The full contents of the supplement are available at https://icm-experimental.springeropen.com/articles/supplements/volume-8-supplement-1. Authors’ contributions R.M., P.P., M.J.S., P.R.M.R., and P.L.S. wrote the manuscript and revised the final version. All authors read and approved the final version of the manuscript. Funding The Brazilian Council for Scientific and Technological Development (CNPq) funded research projects and scholarships for students, Rio de Janeiro State Research Foundation (FAPERJ) funded research projects and scholarships for students, Coordination for the Improvement of Higher Education Personnel (CAPES) funded publication costs and scholarships for students, the Department of Science and Technology—Brazilian Ministry of Health (DECIT/MS) funded research projects, and the National Institute of Science and Technology for Regenerative Medicine/CNPq funded research projects. Availability of data and materials Not applicable Ethics approval and consent to participate Not applicable Consent for publication Not applicable Competing interests None reported ==== Refs References 1. Matthay MA Ware LB Zimmerman GA The acute respiratory distress syndrome J Clin Invest 2012 122 8 2731 2740 10.1172/JCI60331 22850883 2. Force ADT Ranieri VM Rubenfeld GD Thompson BT Ferguson ND Caldwell E Acute respiratory distress syndrome: the Berlin Definition JAMA 2012 307 23 2526 2533 22797452 3. Herwig MC Tsokos M Hermanns MI Kirkpatrick CJ Muller AM Vascular endothelial cadherin expression in lung specimens of patients with sepsis-induced acute respiratory distress syndrome and endothelial cell cultures Pathobiology 2013 80 5 245 251 10.1159/000347062 23635392 4. Matthay MA Zemans RL Zimmerman GA Arabi YM Beitler JR Mercat A Acute respiratory distress syndrome Nat Rev Dis Primers 2019 5 1 18 10.1038/s41572-019-0069-0 30872586 5. Bachofen M Weibel ER Structural alterations of lung parenchyma in the adult respiratory distress syndrome Clin Chest Med 1982 3 1 35 56 7075161 6. Silversides JA Major E Ferguson AJ Mann EE McAuley DF Marshall JC Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis Intensive Care Med 2017 43 2 155 170 10.1007/s00134-016-4573-3 27734109 7. Malbrain M Van Regenmortel N Saugel B De Tavernier B Van Gaal PJ Joannes-Boyau O Principles of fluid management and stewardship in septic shock: it is time to consider the four D's and the four phases of fluid therapy Ann Intensive Care 2018 8 1 66 10.1186/s13613-018-0402-x 29789983 8. Woodcock TE Woodcock TM Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy Br J Anaesth 2012 108 3 384 394 10.1093/bja/aer515 22290457 9. Myburgh JA Mythen MG Resuscitation fluids N Engl J Med 2013 369 25 2462 2463 24350966 10. Adamson RH Lenz JF Zhang X Adamson GN Weinbaum S Curry FE Oncotic pressures opposing filtration across non-fenestrated rat microvessels J Physiol 2004 557 Pt 3 889 907 10.1113/jphysiol.2003.058255 15073281 11. Pries AR Secomb TW Gaehtgens P The endothelial surface layer Pflugers Arch 2000 440 5 653 666 10.1007/s004240000307 11007304 12. Chappell D Bruegger D Potzel J Jacob M Brettner F Vogeser M Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx Crit Care 2014 18 5 538 10.1186/s13054-014-0538-5 25497357 13. Berg S Engman A Hesselvik JF Laurent TC Crystalloid infusion increases plasma hyaluronan Crit Care Med 1994 22 10 1563 1567 10.1097/00003246-199410000-00010 7924366 14. van Golen RF Reiniers MJ Vrisekoop N Zuurbier CJ Olthof PB van Rheenen J The mechanisms and physiological relevance of glycocalyx degradation in hepatic ischemia/reperfusion injury Antioxid Redox Signal 2014 21 7 1098 1118 10.1089/ars.2013.5751 24313895 15. Steppan J Hofer S Funke B Brenner T Henrich M Martin E Sepsis and major abdominal surgery lead to flaking of the endothelial glycocalix J Surg Res 2011 165 1 136 141 10.1016/j.jss.2009.04.034 19560161 16. Nieuwdorp M Mooij HL Kroon J Atasever B Spaan JA Ince C Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes Diabetes. 2006 55 4 1127 1132 10.2337/diabetes.55.04.06.db05-1619 16567538 17. Johansson PI Stensballe J Rasmussen LS Ostrowski SR A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients Ann Surg 2011 254 2 194 200 10.1097/SLA.0b013e318226113d 21772125 18. Zausig YA Chappell D Becker BF Potschka D Busse H Nixdorf K The impact of crystalloidal and colloidal infusion preparations on coronary vascular integrity, interstitial oedema and cardiac performance in isolated hearts Crit Care 2013 17 5 R203 10.1186/cc12898 24034366 19. Rehm M Bruegger D Christ F Conzen P Thiel M Jacob M Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia Circulation. 2007 116 17 1896 1906 10.1161/CIRCULATIONAHA.106.684852 17923576 20. Hofmann-Kiefer KF Kemming GI Chappell D Flondor M Kisch-Wedel H Hauser A Serum heparan sulfate levels are elevated in endotoxemia Eur J Med Res 2009 14 526 531 10.1186/2047-783X-14-12-526 20149986 21. Nelson A Berkestedt I Schmidtchen A Ljunggren L Bodelsson M Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma Shock. 2008 30 6 623 627 10.1097/SHK.0b013e3181777da3 18497712 22. Sallisalmi M Tenhunen J Yang R Oksala N Pettila V Vascular adhesion protein-1 and syndecan-1 in septic shock Acta Anaesthesiol Scand 2012 56 3 316 322 10.1111/j.1399-6576.2011.02578.x 22150439 23. National Heart L, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials N, Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354(24):2564-2575. 24. Semler MW Marney AM Rice TW Nian H Yu C Wheeler AP B-type natriuretic peptide, aldosterone, and fluid management in ARDS Chest. 2016 150 1 102 111 10.1016/j.chest.2016.03.017 27018313 25. Jolley SE Hough CL Clermont G Hayden D Hou S Schoenfeld D Relationship between race and the effect of fluids on long-term mortality after acute respiratory distress syndrome. Secondary Analysis of the National Heart, Lung, and Blood Institute Fluid and Catheter Treatment Trial Ann Am Thorac Soc 2017 14 9 1443 1449 10.1513/AnnalsATS.201611-906OC 28708421 26. Van der Mullen J Wise R Vermeulen G Moonen PJ Malbrain M Assessment of hypovolaemia in the critically ill Anaesthesiol Intensive Ther 2018 50 2 141 149 10.5603/AIT.a2017.0077 29182211 27. Weil MH Henning RJ New concepts in the diagnosis and fluid treatment of circulatory shock. Thirteenth annual Becton, Dickinson and Company Oscar Schwidetsky Memorial Lecture Anesth Analg 1979 58 2 124 132 10.1213/00000539-197903000-00013 571235 28. Monnet X Teboul JL Passive leg raising: five rules, not a drop of fluid! Crit Care 2015 19 18 10.1186/s13054-014-0708-5 25658678 29. Bentzer P Griesdale DE Boyd J MacLean K Sirounis D Ayas NT Will this hemodynamically unstable patient respond to a bolus of intravenous fluids? JAMA 2016 316 12 1298 1309 10.1001/jama.2016.12310 27673307 30. Mahjoub Y Lejeune V Muller L Perbet S Zieleskiewicz L Bart F Evaluation of pulse pressure variation validity criteria in critically ill patients: a prospective observational multicentre point-prevalence study Br J Anaesth 2014 112 4 681 685 10.1093/bja/aet442 24374504 31. Monnet X Marik PE Teboul JL Prediction of fluid responsiveness: an update Ann Intensive Care 2016 6 1 111 10.1186/s13613-016-0216-7 27858374 32. Michard F Teboul JL Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence Chest 2002 121 6 2000 2008 10.1378/chest.121.6.2000 12065368 33. Jozwiak M Depret F Teboul JL Alphonsine JE Lai C Richard C Predicting fluid responsiveness in critically ill patients by using combined end-expiratory and end-inspiratory occlusions with echocardiography Crit Care Med 2017 45 11 e1131 e11e8 10.1097/CCM.0000000000002704 28857907 34. Xu LY Tu GW Cang J Hou JY Yu Y Luo Z End-expiratory occlusion test predicts fluid responsiveness in cardiac surgical patients in the operating theatre Ann Transl Med 2019 7 14 315 10.21037/atm.2019.06.58 31475185 35. Depret F Jozwiak M Teboul JL Alphonsine JE Richard C Monnet X Esophageal doppler can predict fluid responsiveness through end-expiratory and end-inspiratory occlusion tests Crit Care Med 2019 47 2 e96 e102 10.1097/CCM.0000000000003522 30379670 36. Guinot PG Godart J de Broca B Bernard E Lorne E Dupont H End-expiratory occlusion manoeuvre does not accurately predict fluid responsiveness in the operating theatre Br J Anaesth 2014 112 6 1050 1054 10.1093/bja/aet582 24598390 37. Yonis H Bitker L Aublanc M Perinel Ragey S Riad Z Lissonde F Change in cardiac output during Trendelenburg maneuver is a reliable predictor of fluid responsiveness in patients with acute respiratory distress syndrome in the prone position under protective ventilation Crit Care 2017 21 1 295 10.1186/s13054-017-1881-0 29208025 38. Chian CF Tsao CM Chen SJ Chen ZF Liaw WJ Ka SM Hyperoncotic albumin attenuates lung and intestine injuries caused by peritonitis-induced sepsis in rats J Surg Res 2013 182 1 134 141 10.1016/j.jss.2012.08.047 23088918 39. Powers KA Kapus A Khadaroo RG He R Marshall JC Lindsay TF Twenty-five percent albumin prevents lung injury following shock/resuscitation Crit Care Med 2003 31 9 2355 2363 10.1097/01.CCM.0000084846.45830.AA 14501967 40. Morgan TJ The ideal crystalloid - what is ‘balanced’? Curr Opin Crit Care 2013 19 4 299 307 10.1097/MCC.0b013e3283632d46 23743589 41. Robert Valeri C Veech RL The unrecognized effects of the volume and composition of the resuscitation fluid used during the administration of blood products Transfus Apher Sci 2012 46 2 121 123 10.1016/j.transci.2012.01.010 22364841 42. Hahn RG Lyons G The half-life of infusion fluids: an educational review Eur J Anaesthesiol 2016 33 7 475 482 10.1097/EJA.0000000000000436 27058509 43. Chowdhury AH Cox EF Francis ST Lobo DN A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte(R) 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers Ann Surg 2012 256 1 18 24 10.1097/SLA.0b013e318256be72 22580944 44. Yunos NM Bellomo R Hegarty C Story D Ho L Bailey M Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults Jama 2012 308 15 1566 1572 10.1001/jama.2012.13356 23073953 45. McCluskey SA Karkouti K Wijeysundera D Minkovich L Tait G Beattie WS Hyperchloremia after noncardiac surgery is independently associated with increased morbidity and mortality: a propensity-matched cohort study Anesth Analg 2013 117 2 412 421 10.1213/ANE.0b013e318293d81e 23757473 46. Raghunathan K Shaw A Nathanson B Sturmer T Brookhart A Stefan MS Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis* Crit Care Med 2014 42 7 1585 1591 10.1097/CCM.0000000000000305 24674927 47. Young P Bailey M Beasley R Henderson S Mackle D McArthur C Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT Randomized Clinical Trial JAMA 2015 314 16 1701 1710 10.1001/jama.2015.12334 26444692 48. Barea-Mendoza J Chico-Fernandez M Montejo-Gonzalez JC Balanced crystalloids versus saline in critically ill adults N Engl J Med 2018 378 20 1950 1951 29770681 49. Semler MW Self WH Rice TW Balanced crystalloids versus saline in critically ill adults N Engl J Med 2018 378 20 1951 29768150 50. Self WH Semler MW Wanderer JP Wang L Byrne DW Collins SP Balanced crystalloids versus saline in noncritically ill adults N Engl J Med 2018 378 9 819 828 10.1056/NEJMoa1711586 29485926 51. Finfer S Myburgh J Bellomo R Intravenous fluid therapy in critically ill adults Nat Rev Nephrol 2018 14 9 541 557 10.1038/s41581-018-0044-0 30072710 52. Wiedermann CJ Joannidis M Albumin replacement in severe sepsis or septic shock N Engl J Med 2014 371 1 83 10.1056/NEJMc1405675 24988572 53. Claus RA Sossdorf M Hartog C The effects of hydroxyethyl starch on cultured renal epithelial cells Anesth Analg 2010 110 2 300 301 10.1213/ANE.0b013e3181ca03a4 20081129 54. Wiedermann CJ Joannidis M Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review Intensive Care Med 2014 40 2 160 170 10.1007/s00134-013-3156-9 24257970 55. Vincent JL Russell JA Jacob M Martin G Guidet B Wernerman J Albumin administration in the acutely ill: what is new and where next? Crit Care 2014 18 4 231 10.1186/cc13991 25042164 56. Martin GS Mangialardi RJ Wheeler AP Dupont WD Morris JA Bernard GR Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury Crit Care Med 2002 30 10 2175 2182 10.1097/00003246-200210000-00001 12394941 57. Fanali G di Masi A Trezza V Marino M Fasano M Ascenzi P Human serum albumin: from bench to bedside Mol Asp Med 2012 33 3 209 290 10.1016/j.mam.2011.12.002 58. Ulldemolins M Roberts JA Rello J Paterson DL Lipman J The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients Clin Pharmacokinet 2011 50 2 99 110 10.2165/11539220-000000000-00000 21142293 59. Demling RH Effect of plasma and interstitial protein content on tissue edema formation Curr Stud Hematol Blood Transfus 1986 53 36 52 10.1159/000413163 60. Zoellner H Hofler M Beckmann R Hufnagl P Vanyek E Bielek E Serum albumin is a specific inhibitor of apoptosis in human endothelial cells J Cell Sci 1996 109 Pt 10 2571 2580 8923218 61. Pinheiro CC Rayol P Gozzani L Reis LM Zampieri G Dias CB The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia Prenat Diagn 2014 34 11 1084 1092 10.1002/pd.4432 24916790 62. Gong H Rehman J Tang H Wary K Mittal M Chaturvedi P HIF2alpha signaling inhibits adherens junctional disruption in acute lung injury J Clin Invest 2015 125 2 652 664 10.1172/JCI77701 25574837 63. Mendes RS Oliveira MV Padilha GA Rocha NN Santos CL Maia LA Effects of crystalloid, hyper-oncotic albumin, and iso-oncotic albumin on lung and kidney damage in experimental acute lung injury Respir Res 2019 20 1 155 10.1186/s12931-019-1115-x 31311539 64. Alexander JS Alexander BC Eppihimer LA Goodyear N Haque R Davis CP Inflammatory mediators induce sequestration of VE-cadherin in cultured human endothelial cells Inflammation. 2000 24 2 99 113 10.1023/A:1007025325451 10718113 65. Saffarzadeh M Juenemann C Queisser MA Lochnit G Barreto G Galuska SP Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones PLoS One 2012 7 2 e32366 10.1371/journal.pone.0032366 22389696 66. Hogner K Wolff T Pleschka S Plog S Gruber AD Kalinke U Macrophage-expressed IFN-beta contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia PLoS Pathog 2013 9 2 e1003188 10.1371/journal.ppat.1003188 23468627 67. Neuhaus W Schick MA Bruno RR Schneiker B Forster CY Roewer N The effects of colloid solutions on renal proximal tubular cells in vitro Anesth Analg 2012 114 2 371 374 10.1213/ANE.0b013e3182367a54 22025492 68. Kremer H Baron-Menguy C Tesse A Gallois Y Mercat A Henrion D Human serum albumin improves endothelial dysfunction and survival during experimental endotoxemia: concentration-dependent properties Crit Care Med 2011 39 6 1414 1422 10.1097/CCM.0b013e318211ff6e 21336119 69. Uhlig C Silva PL Deckert S Schmitt J de Abreu MG Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis Crit Care 2014 18 1 R10 10.1186/cc13187 24405693 70. Matthay MA Zimmerman GA Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management Am J Respir Cell Mol Biol 2005 33 4 319 327 10.1165/rcmb.F305 16172252 71. Jorgensen KA Stoffersen E On the inhibitory effect of albumin on platelet aggregation Thromb Res 1980 17 1-2 13 18 10.1016/0049-3848(80)90289-3 6990546 72. Bellomo R Morimatsu H Presneill J French C Cole L Story D Effects of saline or albumin resuscitation on standard coagulation tests Crit Care Resusc 2009 11 4 250 256 20001872 73. Paar M Rossmann C Nusshold C Wagner T Schlagenhauf A Leschnik B Anticoagulant action of low, physiologic, and high albumin levels in whole blood PLoS One 2017 12 8 e0182997 10.1371/journal.pone.0182997 28800610 74. Jacob M Bruegger D Rehm M Welsch U Conzen P Becker BF Contrasting effects of colloid and crystalloid resuscitation fluids on cardiac vascular permeability Anesthesiology. 2006 104 6 1223 1231 10.1097/00000542-200606000-00018 16732094 75. Jacob M Paul O Mehringer L Chappell D Rehm M Welsch U Albumin augmentation improves condition of guinea pig hearts after 4 hr of cold ischemia Transplantation. 2009 87 7 956 965 10.1097/TP.0b013e31819c83b5 19352113 76. Kozar RA Peng Z Zhang R Holcomb JB Pati S Park P Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock Anesth Analg 2011 112 6 1289 1295 10.1213/ANE.0b013e318210385c 21346161